Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections

Klara Westman; Henrik Imberg; Magnus O Wijkman; Irl B Hirsch; Jaakko Tuomilehto; Sofia Dahlqvist; Marcus Lind

doi:10.1016/j.jdiacomp.2021.108110

Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections

J Diabetes Complications. 2022 Mar;36(3):108110. doi: 10.1016/j.jdiacomp.2021.108110. Epub 2021 Dec 28.

Authors

Klara Westman¹, Henrik Imberg², Magnus O Wijkman³, Irl B Hirsch⁴, Jaakko Tuomilehto⁵, Sofia Dahlqvist⁶, Marcus Lind⁶

Affiliations

¹ Department of Medicine, NU-Hospital Group, Trollhättan, Uddevalla, Sweden; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address: [email protected].
² Statistiska Konsultgruppen, Gothenburg, Sweden; Department of Mathematical Sciences, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.
³ Department of Internal Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Norrköping, Sweden.
⁴ University of Washington School of Medicine, UW Medicine Diabetes Institute, Seattle, WA 98109, USA.
⁵ Public Health Promotion Unit, Finnish Institute for Health and Welfare, P.O. Box 30, 00271 Helsinki, Finland; Department of Public Health, University of Helsinki, 00014 Helsinki, Finland; Saudi Diabetes Research Group, King Abdulaziz University, 21589 Jeddah, Saudi Arabia.
⁶ Department of Medicine, NU-Hospital Group, Trollhättan, Uddevalla, Sweden; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

PMID: 35101325
DOI: 10.1016/j.jdiacomp.2021.108110

Abstract

In this post-hoc analysis of data from a randomised clinical trial, we compared the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections. Liraglutide increased insulin secretion, measured by C-peptide, by 19% after 24 weeks of treatment. CLINICAL TRIAL REGISTRATION: EudraCT 2012-001941-42.

Keywords: GLP-1 analogues; Insulin secretion; Multiple daily insulin injections; Type 2 diabetes mellitus.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2* / drug therapy
Glycated Hemoglobin / analysis
Humans
Hypoglycemic Agents / therapeutic use
Insulin / therapeutic use
Liraglutide* / adverse effects

Substances

Blood Glucose
Glycated Hemoglobin A
Hypoglycemic Agents
Insulin
Liraglutide

Associated data

EudraCT/2012-001941-42